Use of Raltegravir in Pediatric HIV-1 Infection

Marcia L. Buck, Pharm.D., FCCP, FPPAG; Kristi N. Hofer, Pharm.D; Michelle W. McCarthy, Pharm.D.; FASHP Susan B. Cogut, Pharm.D


Pediatr Pharm. 2012;18(1) 

In This Article


Since its introduction in 2007, raltegravir has been a valuable addition to the options available for treatment of HIV-1 infection. The availability of new study data confirming its safety and efficacy in children, as well as the introduction of a chewable dosage formulation, extend the benefits of raltegravir to the pediatric population.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: